Zealand Pharma A/S (OTCPK:ZLDPF)

$ 89.65 -1.05 (-1.16%) Market Cap: 5.58 Bil Enterprise Value: 5.41 Bil PE Ratio: 0 PB Ratio: 13.50 GF Score: 56/100

Q1 2024 Zealand Pharma A/S Earnings Call Transcript
6 days ago

$91.15 (-4.36%)

Earnings
Full Year 2023 Zealand Pharma A/S Earnings Call Transcript
Feb 27, 2024

$90 (-12.62%)

Earnings
Zealand Pharma A/S at Goldman Sachs Healthcare C-Suite Unscripted Conference Transcript
Jan 04, 2024
Zealand Pharma A/S Obesity R&D Event Transcript
Dec 05, 2023
Q3 2023 Zealand Pharma A/S Earnings Call Transcript
Nov 09, 2023

$41.91

Earnings
Zealand Pharma A/S at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Zealand Pharma A/S Earnings Call Transcript
Aug 17, 2023

$35.19 (-0.45%)

Earnings
Zealand Pharma A/S at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Zealand Pharma A/S at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Q1 2023 Zealand Pharma A/S Earnings Call Transcript
May 11, 2023

$35 (+7.36%)

Earnings
Zealand Pharma A/S at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
Zealand Pharma A/S Annual Shareholders Meeting Transcript
Mar 29, 2023
Q4 2022 Zealand Pharma A/S Earnings Call Transcript
Mar 02, 2023

$32

Earnings
Zealand Pharma A/S at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
Q3 2022 Zealand Pharma A/S Earnings Call Transcript
Nov 10, 2022

$26.48

Earnings
Zealand Pharma A/S Corporate Call Transcript
Sep 30, 2022
Zealand Pharma A/S at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Q2 2022 Zealand Pharma A/S Earnings Call Transcript
Aug 11, 2022

$18.3 (+0.94%)

Earnings
Q1 2022 Zealand Pharma A/S Earnings Call Transcript
May 12, 2022

$11.14

Earnings
Zealand Pharma A/S at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Zealand Pharma A/S Corporate Update Call Transcript
Mar 30, 2022
Q4 2021 Zealand Pharma A/S Earnings Call Transcript
Mar 10, 2022

$14.35

Earnings
Q3 2021 Zealand Pharma A/S Earnings Call Transcript
Nov 11, 2021

$27.5 (-13.11%)

Earnings
Zealand Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Q2 2021 Zealand Pharma A/S Earnings Call Transcript
Aug 12, 2021

$28.92

Earnings
Zealand Pharma A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Q1 2021 Zealand Pharma A/S Earnings Call Transcript
May 12, 2021

$32.6

Earnings
Zealand Pharma A/S Corporate Call Transcript
Mar 23, 2021
Full Year 2020 Zealand Pharma A/S Earnings Call Transcript
Mar 11, 2021

$31.88

Earnings
Zealand Pharma A/S - Special Call Transcript
Mar 05, 2021
Zealand Pharma A/S - Pre Recorded Special Call Transcript
Mar 04, 2021
Q3 2020 Zealand Pharma A/S Earnings Call Transcript
Nov 12, 2020

$33.4

Earnings
Zealand Pharma A/S Presents at Morgan Stanley 18th Annual Global Healthcare Conference, Sep-14-2020 10:30 AM Transcript
Sep 14, 2020
Q2 2020 Zealand Pharma A/S Earnings Call Transcript
Aug 13, 2020

$35.63

Earnings
Q1 2020 Zealand Pharma A/S Earnings Call Transcript
May 14, 2020

$24.6

Earnings
Zealand Pharma A/S at Needham Healthcare Conference Transcript
Apr 15, 2020
Zealand Pharma A/S Annual Shareholders Meeting Transcript
Apr 02, 2020
Full Year 2019 Zealand Pharma A/S Earnings Call Transcript
Mar 12, 2020

$25.7 (-28.31%)

Earnings
Valeritas Holdings, Inc., Zealand Pharma A/S - M&A Call Transcript
Feb 10, 2020
Q3 2019 Zealand Pharma A/S Earnings Call Transcript
Nov 14, 2019

$33.1 (+3.70%)

Earnings
Zealand Pharma A/S Expands Its Peptide Platform with Acquisition of Encycle Therapeutics Inc Call Transcript
Oct 22, 2019
Half Year 2019 Zealand Pharma A/S Earnings Call Transcript
Aug 15, 2019

$21.86

Earnings
Q1 2019 Zealand Pharma A/S Earnings Call Transcript
May 16, 2019

$20.42

Earnings
Zealand Pharma A/S - Special Call Transcript
Mar 21, 2019
Q4 2018 Zealand Pharma A/S Earnings Call Transcript
Mar 07, 2019

$13.77

Earnings

Zealand Pharma A/S Obesity R&D Event Transcript

Dec 05, 2023 / 01:30PM GMT

Release Date Price: $47.92

Transcript

Anna Krassowska Zealand Pharma A;S;VP

Head of IR & Corporate Communications

/- -

So I wanted to welcome everyone, and thank you for joining us today here in London and everyone who's also joining us online. I'm Anna Krassowska, I'm Head of Investor Relations and Communications at Zealand Pharma, and we are very excited to be here today to discuss the future of obesity management. How we believe the mechanisms that we are pursuing and in particular the peptides that we are developed, they shape a future treatment of obesity.

So please be aware, therefore, that we will be making forward-looking statements today that carry risks and uncertainties and actual results may differ from these forward-looking statements.

So for the agenda today, we will start by framing the global obesity pandemic that we are facing today. And then this will be followed by three presentations that cover the scientific mechanisms and the clinical potential of the candidates in our pipeline.

So first, we'll start with our two wholly-owned candidates, our GLP-1, GLP-2

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.